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DNA topoisomerases are the targets of important anticancer and antibacterial drugs. Camptothecins and
novel noncamptothecins in clinical development (indenoisoquinolines and ARC-111) target eukaryotic
type IB topoisomerases (Top1), whereas human type IIA topoisomerases (Top2a and Top2b) are the targets
of the widely used anticancer agents etoposide, anthracyclines (doxorubicin, daunorubicin), and mitoxan-
trone. Bacterial type II topoisomerases (gyrase and Topo IV) are the targets of quinolones and aminocou-
marin antibiotics. This review focuses on the molecular and biochemical characteristics of topoisomerases
and their inhibitors. We also discuss the common mechanism of action of topoisomerase poisons by inter-
facial inhibition and trapping of topoisomerase cleavage complexes.Topological Constraints of DNA
DNA strand separation for transcription and replication, the
flawless segregation of two identical copies of entire genomes
in two daughter cells following replication, and the formidable
genomic compaction in cells exemplify the critical actions of
DNA topoisomerases (Wang, 2009b).
DNA compaction is such that the entire genome of a single
human cell (3 3 109 base pairs corresponding to approximately
1.8 m) needs to be squeezed into a nucleus with an average
diameter of 6 mm. In other words, the circumference of an
average mammalian cell nucleus is almost one million times
smaller than the length of the genome that needs to be packed
into it. Even the smaller circular Escherichia coli genome (4.7 3
106 base pairs) needs to be compacted within a bacterial cell
whose average circumference is 3000 times smaller. Tomaintain
DNA compacted, topoisomerases are required to avoid super-
helical tension and knots.
DNA strand separation is obligatory to transcribe and replicate
genomes by copying each base by RNA and DNA polymerases.
Because of the DNA double-helical structure and lack of free
rotation in cells, strand separation generates DNA supercoiling
in the flanking regions where the two strands are separated by
the polymerase-helicase complexes. As a result, positive super-
coiling is generated in front of the replication or transcription
sites and negative supercoiling behind (Liu and Wang, 1987).
Without the action of DNA topoisomerases, positive supercoiling
rapidly stalls replication and transcription and negative super-
coiling favors the formation of abnormal DNA structures
including D loops (invasion of a DNA duplex by a complementary
single-stranded DNA segment), R loops (persistent annealing of
RNA with its DNA template behind RNA polymerase), guanosine
quartets, and Z-DNA, all of which interfere with normal DNA
metabolism.
Replicating the whole genome needs to be accomplished
within one cell cycle (i.e., by multiple replication forks with an
average velocity of 2 kilobases per minute per fork in a human
cell). Because of DNA’s double-helical structure, replication
generates catenated progenies that have to be unlinked byChemistry & Btopoisomerases prior to cytokinesis. In addition, in circular
bacterial or viral genomes, replication forms obligatory cate-
nanes (this can easily be realized by cutting a Mobius strip along
its longitudinal axis).
Classification and Nomenclature
The human genome encodes six topoisomerases and E. coli four
(Figure 1A). Topoisomerases are classified as type I and type II
(Forterre et al., 2007; Schoeffler and Berger, 2008; Wang,
2009b). Type I enzymes cleave one DNA strand at a time and
type II both strands to perform their catalytic functions (Figures
1C–1H). All topoisomerases cleave the DNA phosphodiester
backbone by nucleophilic attack from a catalytic tyrosine residue
which becomes linked to the phosphate end (P-Y) of the DNA
break (Figures 1C–1H). Those reactions are highly reversible
and leave the DNA sequence unchanged following topoisomeri-
zation.
Type I topoisomerases are further subdivided into type IA and
IB. E. coli type IA topoisomerase (Figure 1B), the first topoiso-
merase discovered, was initially named ‘‘u protein’’ because it
was purified by ultracentrifugation that uses u as a parameter
of angular velocity (Wang, 1971). Eukaryotic Top1 (Figure 1A)
(Champoux and Dulbecco, 1972) is classified as type IB
because of two key differences with E. coli Topo I. First, it
relaxes both negative and positive supercoils, whereas E. coli
Topo I only relaxes negative supercoils. Second, it cleaves
DNA by forming a tyrosyl-DNA covalent catalytic intermediate
at the 30 end of the break (30-P-Y; Figure 1D), whereas E. coli
Topo I forms a 50-P-Y intermediate. Eukaryotic type IA, named
Top3, was identified through genomic homology search (Hanai
et al., 1996). Vertebrates encode two Top3 enzymes (Top3a
and b). Both form 50-P-Y covalent intermediates and only relax
negatively supercoiled DNA (only increasing the DNA linking
number; Lk) (Figure 1A). The last discovered human topoisomer-
ase is Top1mt, a type IB enzyme encoded in the nuclear
genome but which operates on mitochondrial DNA (Zhang
et al., 2001). In vertebrates, only Top1 and Top1mt form cova-
lent linkages to the 30 end of the breaks (Figure 1A). All the otheriology 17, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 421
Figure 1. Overview ofDNATopoisomerases
(A) Classification of human DNA topoisomerases.
kDa: molecular masses calculated from polypep-
tide composition. (x2): dimer. Type IB are the
only enzymes that form cleavage complexes (cc)
with 30-phosphotyrosyl (30-P-Y) intermediates.
DLk: linking number change produced by each
catalytic cycle. Type I enzymes change Lk in steps
of one and type II in steps of two as they cleave
one and both strands of DNA, respectively. Type
IA enzymes are the only enzymes that relax only
negative but not positive supercoiling (DLk = +1).
(B) Classification of E. coli DNA topoisomerases.
(C) Noncovalent binding of type IB enzymes.
(D) Scheme of the 30-phosphotyrosine covalent
bond in the Top1cc. The arrow indicates the
reversible (religation) reaction, which is favored
under normal conditions.
(E) Trapping of the cleavage complex by campto-
thecin (CPT) and the Top1 inhibitors (see Figure 3).
(F) Noncovalent binding of type IIA enzyme homo-
dimers (A2B2 and C2E2 in the case of gyrase and
Topo IV, respectively).
(G) Scheme of the 50-phosphotyrosine covalent
bond in the Top2cc. The arrow indicates the
reversible (religation) reaction, which is favored
under normal conditions. Note the four base pair
stagger with 50-overhang on opposite strands
characteristic of all type IIA enzymes.
(H) Trapping of the cleavage complex by etopo-
side, doxorubicin, or quinolones (see Figure 3).
Note that some Top2 poisons increase the
steady-state levels of Top2cc by increasing
cleavage (ellipticines, azatoxin, quinolones, and
isoflavones).
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respect, Top1 and Top1mt (type IB eukaryotic topoisomerases)
belong to the family of tyrosine recombinases which also
includes XerCD of E. coli, Cre of the P1 phage, Flip (FLP) of
yeast Saccharomyces cerevisiae, and l integrase of lambda
phage. However, no recombinase function has been assigned
to Top1 in cells.
Bacteria tend to have a simpler organization than vertebrates,
with only four topoisomerases in E. coli (Figure 1B). However,
bacteria have two type IA enzymes (Topo I and Topo III) and
two type IIA enzymes (gyrase and Topo IV).
Functional Size of Topoisomerases
Topoisomerases are large proteins (Figures 1A and 1B). The
functional sizes of the bacterial and eukaryotic enzyme
complexes range from 70 kDa (for Top1mt and bacterial Topo I)
to 370–400 kDa (for the type II enzymes that function as multi-
mers) (Figures 1F–1H). In comparison, the size of a nucleosome
is 120 kDa without histone H1 and 180 kDa with H1 (i.e., more
than 2-fold smaller).
Note regarding the following sections: we will not discuss
further the type IA topoisomerases (bacterial Topo I and human
Top3) and type IIB topoisomerases because they are not yet
clinical therapeutic targets. Further information regarding type
IA and IIB enzymes and the targeting of bacterial type IA
enzymes can be found in several detailed reviews (Schoeffler
and Berger, 2008; Tse-Dinh, 2009; Wang, 2002, 2009a).422 Chemistry & Biology 17, May 28, 2010 ª2010 Elsevier Ltd All righType IB Topoisomerases and Their Targeting
by Anticancer Drugs
Eukaryotic Nuclear Top1
All eukaryotes encode at least one type IB topoisomerase gene
(TOP1). TOP1 is essential in Drosophila (Lee et al., 1993) and
vertebrates but not in yeast (Goto and Wang, 1985; Uemura
and Yanagida, 1984). Mouse embryos lacking TOP1 die early
before the fertilized egg gets to the eight-cell stage (Morham
et al., 1996). Only one murine cell line (p388/CPT45) selected
for resistance to camptothecin (CPT) grows with almost unde-
tectable levels of Top1 (Eng et al., 1990; Tuduri et al., 2009),
and the two human cell lines recently generated by stable
Top1 knockdown express 10%–20% of normal Top1 levels
(Miao et al., 2007). Those cells accumulate spontaneous
genomic alterations and replication defects (Miao et al., 2007;
Tuduri et al., 2009). They also exhibit altered gene expression
(Miao et al., 2007), reflecting the critical importance of Top1 nick-
ing-closing activity via formation of Top1-DNA cleavage
complexes (Top1cc) (Figure 2C) for DNA relaxation during repli-
cation and transcription. Human Top1 also has transcriptional
activities independent of DNA nicking-closing activity: promoter
regulation (Merino et al., 1993) and phosphorylation/activation of
splicing factors (Rossi et al., 1998; Soret et al., 2003).
Vertebrate Mitochondrial Top1
TOP1mt is present in the nuclear genome of vertebrates (Zhang
et al., 2004, 2007) (Figure 2A). Similarities between TOP1mt and
TOP1 (Figure 2A) suggest they probably originated from thets reserved
Figure 2. Overview of Type IB
Topoisomerases and Relaxation
by Nicking-Closing Activity
(A) Schematic representation of the two human
type IB enzymes. Top1mt has a much shorter
N-terminal segment consisting primarily of a mito-
chondrial targeting sequence (MTS) and lacking
the nuclear localization sequences (NLS) of Top1
(nuclear). The catalytic homologous residues are
indicated with their position.
(B) Schematic representation of the poxvirus
(variola and vaccinia) Top1s and comparison
with the recently discovered bacterial Top1B
(Pseudomonas aeroginosa).
(C) Top1-mediated DNA relaxation by controlled
rotation. By contrast to type IA or II enzymes,
this reaction does not require an energy cofactor
or divalent metal. Top1 tends to bind DNA cross-
overs (supercoils) and nicks DNA by transesterifi-
cation (see Figure 1D). The enzyme then allows
the DNA to swivel by controlled rotation (Koster
et al., 2005; Stivers et al., 1997). Upon DNA
realignment by base pairing and stacking across
the nick, the DNA 50-hydroxyl end (OH in lower
panels) removes the tyrosyl linkage by reverse
transesterification (see Figure 1D).
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(Zhang et al., 2004). Top1mt binds to the region flanking the
end of the replication D loop at the putative attachment site of
nucleoids to the mitochondrial inner membrane (Zhang and
Pommier, 2008). In spite of its conservation in all vertebrates,
TOP1mt is dispensable in mice (Zhang et al., 2007), indicating
complementation by another topoisomerase (Low et al., 2003;
Zhang et al., 2007). Top1mt is sensitive to CPT (Zhang et al.,
2001; Zhang and Pommier, 2008) but is unlikely to be targeted
by the drug in cells because the mitochondria matrix is alkaline
(Zhang et al., 2001), which inactivates CPT (see Figure 3 and
section below).
Viral and Bacterial Type IB Enzymes
Poxviruses (vaccinia and variola) encode one topoisomerase,
which is the smallest topoisomerase (314 residues; 37 kDa)
(Figure 2B). Vaccinia and variola Top1s are similar except for
three amino acid residues. They contain the conserved catalytic
residues R, K, R, H found in the core domain of eukaryotic Top1
and Top1mt, but lack the linker region (Figure 2A). The poxvirus
Top1s are required because the host Top1 is restricted to the
nucleus and poxviruses replicate in the cytoplasm. Poxvirus
Top1s cleave DNA with greater sequence selectivity (at CCTTT
recognition sequences; Shuman, 1998) than eukaryotic Top1s
and are immune to camptothecins. Vaccinia Top1 acts as a
very efficient recombinase and is used as a cloning toolChemistry & Biology 17, May 28, 2010(TOPO-TA Cloning; Invitrogen) (Shuman,
1989). Poxvirus Top1s are potential
weapons in the context of bioterrorism.
Type IB genes have been found in
some bacteria including Pseudomonas
aeroginosa and the radiation-resistant
Deinococcus radiodurans. They are
structurally related to the poxvirus
Top1s, suggesting they arose from a
common ancestor strand transferasewith tyrosine recombinases (Krogh and Shuman, 2002). Whether
the bacterial (and viral) type IB topoisomerases act as recombi-
nases and/or DNA-relaxing enzymes remain to be determined.
No effective inhibitor exists, although they may represent novel
antibacterial targets.
Anticancer Top1 Inhibitors
CPT was first identified from the Chinese tree Camptotheca
acuminata (Wall et al., 1966; Wall and Wani, 1995). It poisons
Top1cc by reversibly inhibiting its religation (Hsiang et al.,
1985) (Figure 1E). Four lines of evidence demonstrate the selec-
tive poisoning of Top1 by CPT (reviewed in Pommier, 2006,
2009): (1) only the natural CPT isomer is active against Top1
(Hsiang et al., 1989; Jaxel et al., 1989); (2) genetically modified
yeast deleted for TOP1 (Top1D) is immune to CPT (Eng et al.,
1988); (3) cells selected for CPT resistance harbor precise and
causal point mutations in the TOP1 gene (Pommier et al.,
1999); and (4) CPT-producing plants bear a point mutation in
Top1 (N722S) (Sirikantaramas et al., 2008) that also renders
the enzyme immune to CPT (Fujimori et al., 1995).
Three water-soluble CPT derivatives are approved for clinical
use: topotecan, irinotecan (worldwide), and belotecan (in South
Korea) (Figure 3A). In spite of their established anticancer activity,
camptothecins have a major limitation. They are inactivated
within minutes at physiological pH by lactone E ring opening
(Figure 3A). Derivatives (gimatecan, belotecan, lurtotecan, andª2010 Elsevier Ltd All rights reserved 423
Figure 3. Top1 Inhibitors
(A) Camptothecin and its clinical derivatives. The facile and reversible opening of the a-hydroxylactone E ring of camptothecin is shown at the top. Topotecan and
irinotecan are the two FDA-approved camptothecins. Irinotecan is a prodrug; its active metabolite is SN-38. Belotecan is approved in South Korea.
(B) Synthetic E-ring-modified camptothecin derivatives. Whereas diflomotecan (a homocamptothecin) can still be converted irreversibly to a carboxylate, the
a-keto derivative S39625 is chemically stable while still being a potent Top1 inhibitor.
(C) Noncamptothecins. The indenoisoquinolines and one dibenzonaphthyridinone are beginning clinical trials.
Chemistry & Biology
Reviewexatecan) (Figure 3A) have been developed to improve solubility
and clinical tolerability and allow oral administration. However,
they retain the chemical instability of camptothecins.
Two approaches have been taken to overcome the E ring
instability of camptothecins. Addition of a methylene group in
the E ring, as in the homocamptothecins (Figure 3B), limits E
ring opening (Lavergne et al., 1998) but, once this happens,
they become irreversibly converted to an inactive carboxylate
(Urasaki et al., 2000). In the second approach, conversion of
the E ring to a five-membered ring completely stabilizes the
drug. These a-keto derivatives (Hautefaye et al., 2003) exempli-
fied by S39625 (Figure 3C) (Takagi et al., 2007) are highly potent
synthetic compounds against Top1 and in cancer cells.
The first noncamptothecin Top1 inhibitor (Figure 3C) reaching
clinical trials was edotecarin. However, like other indolocarba-
zoles, it affects other cellular targets besides Top1, including
DNA itself. Two families of noncamptothecin Top1 inhibitors
are beginning clinical development (Pommier and Cushman,
2009; Teicher, 2008): the indenoisoquinolines and the dibenzo-424 Chemistry & Biology 17, May 28, 2010 ª2010 Elsevier Ltd All righnaphthyridinones (Figure 3C). Both are synthetic and chemically
stable, thereby overcoming the E-ring-opening inactivation of
camptothecins. They also overcome the drug efflux-associated
resistance of camptothecins and produce more stable cleavage
complexes at different genomic locations compared to campto-
thecins (Pommier and Cushman, 2009; Teicher, 2008). The
aromathecins (Figure 3C) are at an earlier stage of development
(Cinelli et al., 2009).
Determinants of the Anticancer Activity of Top1
Inhibitors: Importance of Repair andCheckpoint Defects
In spite of the fact thatTop1 is the sole targetof camptothecins, the
molecular determinants of their anticancer activity are complex.
Top1 is required for both normal and cancer cells, and intrinsic
defects in DNA repair and checkpoints, which are the landmarks
of cancer cells, are likely the Achilles’ heels of cancer cells treated
with anti-Top1 drugs (Pommier, 2006; Pommier et al., 2006a).
Drug-stabilized Top1cc are converted into DNA damage by
twomain processes: DNA replication and transcription. Collision
of DNA or RNA polymerase complexes into stalled Top1ccts reserved
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generated by the stalled polymerase cannot reverse the tyro-
sine-phosphodiester bond (see reverse transesterification
reaction in Figure 1D) and thereby generates an irreversible
Top1-DNA crosslink associated with a double-strand end. The
repair of such lesions is only partially understood. At least two
steps need to take place: removal of the Top1 from the 30-DNA
end and religation of the free 50 end.
The best-characterized pathway for the removal of Top1-DNA
adducts implicates tyrosyl-DNA phosphodiesterase 1 (Tdp1)
(Yang et al., 1996) (reviewed inDexheimer et al., 2008). Additional
cellular processes are required in association with Tdp1. Top1
needs to be proteolyzed by the 26S proteasome (Desai et al.,
2001; Lin et al., 2009) before Tdp1 can efficiently process the
tyrosyl-DNA adduct (Debethune et al., 2002; Interthal et al.,
2005; Pouliot et al., 1999). Polynucleotide kinase phosphatase
(PNK) has to remove the 30-phosphate left by Tdp1 to allow the
actions of DNA polymerases and ligases (Pommier et al., 2006a).
Studies in yeast have also demonstrated alternative endonu-
cleolytic repair pathways for removing Top1-DNA complexes.
Rad1XPF/Rad10ERCC1, Mus81/Mms4Emi1, Mre11/Xrs2Nbs1, and
Slx4/Slx1 (reviewed in Pommier et al., 2006a) (human orthologs
in superscripts) can catalyze the endonucleolytic cleavage of
DNA immediately upstream from the Top1-DNA adduct.
A third possibility for the reversal of the trapped Top1cc asso-
ciated with replication fork collisions is by backtracking the DNA
polymerase complex together with the newly replicated DNA.
The Bloom (BLM) helicase has been implicated in such a process
by allowing the reannealing and religation of the cleavage
complex (Pommier et al., 2006a). Consequently, BLM together
with Top3a can resolve the associated double-Holliday junction
(Wu and Hickson, 2006).
One approach to augment the selectivity of Top1 poisons
toward cancer cells is to combine them with Tdp1 inhibitors.
The rationale is derived from yeast experiments showing that
knocking out Tdp1 has minimal impact on the toxicity of CPT
unless the cell is also deficient for Rad9, a key checkpoint
gene in yeast encoding a BRCT-containing protein (Pouliot
et al., 2001). Because cancer cells are commonly defective for
BRCA1, one of the human orthologs of Rad9, Tdp1 inhibitors
are expected to selectively enhance the activity of Top1 inhibi-
tors in cancer cells, which are checkpoint defective, whereas
having minimal impact on normal cells (Dexheimer et al., 2008).
Another approach to increase the selectivity of Top1 inhibitors
toward cancer cells is to combine them with checkpoint kinase
inhibitors. The proof of principle for this combination was initially
established with UCN-01 (7-hydroxystaurosporine), which
shows a remarkable synergy with camptothecin in p53-deficient
cells (Shao et al., 1997). The ongoing development of specific
Chk1 and Chk2 inhibitors should provide promising combina-
tions with Top1 inhibitors (Lapenna and Giordano, 2009; Pom-
mier et al., 2006b).
Several mechanisms are commonly associated with cellular
resistance to camptothecins: drug efflux pump overexpression
(Brangi et al., 1999), reduction of Top1 protein levels (Eng
et al., 1990; Fujimori et al., 1995), and Top1 mutations (Pommier
et al., 1999). Multifactorial resistance is likely in human cancers,
underlining the importance of a multiparametric approach for the
rational use of Top1 inhibitors.Chemistry & BEukaryotic Top2 Enzymes and Their Targeting
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Eukaryotic Top2 Enzymes
Both Top1 and Top2 can remove DNA supercoiling. In yeast,
inactivation of Top1 is compensated by the other topoiso-
merases (Goto and Wang, 1985; Uemura et al., 1987). However,
Top2-deficient yeast strains die at mitosis because Top2 is
essential for chromosome condensation and segregation (Goto
and Wang, 1985). This is because only Top2 can separate inter-
linked duplex DNA circles (catenanes) (see next section). In all
cells, decatenation is essential at the end of replication to enable
the segregation of newly replicated chromosomes.
Mammals (but not yeast or Drosophila) have two isoenzymes,
Top2a and b (Figures 1A and 4A). Top2a is tightly linked to cell
proliferation, whereas Top2b is also expressed in nondividing
cells. Top2a increases 2- to 3-fold during G2/M and is orders
of magnitude higher in rapidly proliferating than in quiescent
cells. Top2a relaxes positively supercoiled DNA more efficiently
than negatively supercoiled DNA. In contrast, Top2b acts on
both similarly (McClendon et al., 2005). Knocking out Top2b is
compatible with embryonic development, but Top2b/mice die
at birth from neurological defects probably related to the critical
role of Top2b in transcription (Ju et al., 2006; Perillo et al., 2008).
Top2 Catalytic Cycle
Top2a and b function as homodimers and require Mg2+ (Figures
4C and 5A) (for more details, see Deweese et al., 2009; Nitiss,
2009b; Schoeffler and Berger, 2008; Wang, 2009a). Like Top1,
Top2 exhibits a relatively ‘‘relaxed’’ sequence selectivity, allow-
ing its action at multiple sites of the genome. The enzyme dimer,
however, preferentially binds DNA crossover regions (DNA
supercoils, knots, catenanes) (Figure 5B). The two DNA
segments are referred to as the G and T segments. The G
(gate) segment is cleaved by the enzyme in order to pass the T
(transported) segment through the enzyme-DNA complex
(Figure 5A). UponATPbinding, Top2undergoes a conformational
change from an open to a closed clamp form (Figure 5A, step 2).
In the presence of Mg2+, the tyrosine from each Top2 monomer
(tyrosine 804 for human Top2a or tyrosine 821 for Top2b;
Figure 4A) attacks a DNA phosphodiester bond four bases apart
on opposite strands of the G duplex and becomes covalently
linked to the 50 ends of the broken DNA (see Figure 1E). The T
segment can then pass through the broken G segment (steps
3 and 4). Under normal conditions, the cleavage complex is short
lived. After strand passage, the T segment is released from the
clamp and the broken ends of the G segment are religated within
the Top2 homodimer complex (steps 5 and 6). ATP hydrolysis
converts the complex back to its open clamp form with release
of the G segment (step 6). Thus, closing and opening of the
Top2 clamp are coupled with ATP binding and hydrolysis.
Through its ability to catalyze strand passage, Top2 can
perform a variety of reactions. DNA relaxation is common to
Top1, whereas catenation-decatenation, and knotting-unknot-
ting, are Top2 specific (Figure 5B).
Anticancer Top2 Poisons and Top2 Inhibitors
Drugs (Figure 6A) poison Top2 cleavage complexes (Top2cc) by
twomechanisms (Figures 1H and 5A). Etoposide (VP-16), tenipo-
side (VM-26), and the DNA intercalators doxorubicin, daunoru-
bicin, amsacrine (m-AMSA), and TAS-103 inhibit DNA religation,
whereas the quinolone CP-115,953, the ellipticines, azatoxins,iology 17, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 425
Figure 4. Structural Overview of the Type
IIA Topoisomerases Targeted by Anticancer
and Antibacterial Drugs
(A) Schematic representation of the human Top2
enzymes Top2a and b. Note the high similarity of
their ATPase and cleavage/religation domains,
whereas their N- and C-terminal regions are
more divergent. Conserved catalytic residues are
indicated including the catalytic tyrosines Y805
and Y821 in Top2a and b, respectively.
(B) Schematic representation of the bacterial Top2
enzymes gyrase and Topo IV. Gyrase is a heterote-
tramer encoded by two genes: GyrA and GyrB
(A2B2; see Figure 1B). Topo IV is also a heterote-
tramer encoded by two genes: ParC and ParE
(C2E2; see Figure 1B). Conserved catalytic resi-
dues are indicated including the catalytic tyrosines
Y122andY120 ingyrase andTopo IV, respectively.
(C) Conserved interaction of type IIA enzymes with
DNAby their TOPRIMmotifs (alignment at left). The
right scheme represents the two-metal-binding
model between the TOPRIMmotif and DNA (modi-
fied from Deweese et al., 2008).
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formation of Top2cc (Figure 5A) (Fortune and Osheroff, 2000).
Inhibition of Top2 catalytic activity without trapping cleavage
complexes is also observed for DNA intercalators at drug con-
centrations that alter DNA structure, thereby preventing Top2
from binding DNA (step 1 in Figure 5A) or from forming Top2cc
(step 3) (Pommier et al., 1984; Tewey et al., 1984). This explains
why doxorubicin poisons Top2cc at low drug concentrations but
suppresses Top2cc at higher concentrations. Non-DNA binders,
such as merbarone and bisdioxopiperazines (ICRF 159, 187
[dexrazoxane], and 193) (Figure 6A), also act by inhibiting ATP
hydrolysis that produces ‘‘closed clamps’’ (steps 5 and 6 in
Figure 5A) without trapping Top2cc.
Top2 poisons differ from each other. As mentioned above,
some act by inhibiting the religation of Top2cc (VP-16, VM-26,
anthracyclines, amsacrine), whereas others induce their forma-
tion (ellipticines, isoflavones, azatoxins, and the quinolone CP-
115,953) (Fortune and Osheroff, 2000). The kinetics of formation
and religation of cellular Top2cc vary from slow in the case of426 Chemistry & Biology 17, May 28, 2010 ª2010 Elsevier Ltd All rights reserveddoxorubicin to very rapid in the case of
VP-16, m-AMSA, and ellipticinium (Long
et al., 1985; Zwelling et al., 1981). Drugs
not only poison Top2-mediated DNA
double-strand breaks (DSB) but also
single-strand breaks (SSB). Ellipticines
produce almost exclusivelyDSB,whereas
VP-16 and amsacrine produce 7–20 SSB
per DSB and anthracyclines an equal
number of SSB and DSB (Long et al.,
1985; Pommier et al., 1984; Zwelling
et al., 1981). The genomic localization of
the Top2cc varies among drug classes
(Capranico et al., 1990; Capranico and
Binaschi, 1998; Fortune and Osheroff,
2000; Pommier et al., 1991). Adenine at
position 1 (see Figure 1F) tends to be
preferred for doxorubicin; cytosine 1 for
VP-16, VM-26, mitoxantrone, amonafide,and quinolones; thymine1 for ellipticines and genistein; adenine
+1 for amsacrine; and guanine +1 for saintopin. Finally, some
inhibitors have additional targets besides Top2. The anthracy-
clines (doxorubicin, daunorubicin, and their derivatives) can affect
a broad range of DNA processes by intercalation and undergo
redox reactions that generate reactive oxygen species (ROS),
which have been implicated in their dose-limiting cardiotoxicity.
Determinants of the Anticancer Activity of Top2 Poisons
Drug-induced Top2cc are not sufficient to fully account for the
anticancer activity of Top2 poisons, as both normal and cancer
cells express Top2. In contrast to camptothecin, DNA synthesis
inhibition provides only partial protection against VP-16 (Holm
et al., 1989). Interferences between the trapped Top2cc and
transcription may play a prominent role, as the cytotoxicity of
VP-16 is decreased by RNA synthesis inhibitors (D’Arpa et al.,
1990). The dependence of Top1 and Top2 inhibitors on ongoing
replication and transcription probably explains why simulta-
neous treatment with camptothecin and VP-16 is antagonistic
(Bertrand et al., 1992; D’Arpa et al., 1990; Kaufmann, 1991).
Figure 5. Catalytic Cycle and Reactions
Carried Out by Type IIA Topoisomerases
(A) Schematic representation of the catalytic cycle
for human Top2 enzymes (see text for details).
Note that doxorubicin can block the catalytic cycle
at two different steps. At low concentration
(<1 mM), doxorubicin acts like etoposide (VP-16)
by blocking DNA religation (between steps 4 and
5). At higher concentrations (>10 mM), doxorubicin
acts like aclarubicin by interfering with Top2
binding to DNA (before step 1). ICRF-187 blocks
ATP hydrolysis and inhibits reopening of the
ATPase domain (between steps 5 and 6), thereby
trapping topological complexes with DNA inside
the enzyme.
(B) Reactions catalyzed by type IIA topoisomer-
ase. Note that Top1 can only catalyze supercoiling
relaxation. Also, in bacteria, Topo IV acts preferen-
tially as the decatenation enzyme, whereas gyrase
acts preferentially in removing positive supercoil-
ing and selectively in generating negative super-
coiling.
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and camptothecin may suppress the effects of VP-16 by inhibit-
ing transcription. The involvement of ROS (Pommier et al., 1983)
remains unexplained, albeit reminiscent of bacterial killing by
quinolones (Drlica et al., 2009).
The repair of Top2cc is poorly understood. As in the case of
Top1, proteosomal degradation of the covalently linked Top2
has been proposed to enable access of DNA repair enzymes
to the broken DNA (Zhang et al., 2006). Recently, a 50-tyrosine
phosphodiesterase (TTRAP/Tdp2) has been identified for the
excision of Top2-DNA adducts (Cortes Ledesma et al., 2009).
In addition, as in the case of Top1, endonucleolytic cleavage
may involve the removal of the trapped Top2 by cleavage of
the DNA near the point of attachment of Top2 to the 50-DNA
end. The 50-flap endonuclease Rad27FEN1 and the end-process-
ing nucleases Mre11 and CtIP have been proposed to act in this
way (Malik and Nitiss, 2004; Nitiss, 2009b).
The cellular response to Top2 inhibitors is complex, and
several mechanisms are commonly associated with cellular
resistance to Top2 inhibitors: Pgp and/or MRP overexpression,Chemistry & Biology 17, May 28, 2010reduction of Top2 protein levels, changes
in subcellular localization, Top2 phos-
phorylation, and Top2 mutations (Nitiss,
2009a, 2009b).
Secondary Malignancies Induced
by Top2 Poisons: Implication
of Top2b
Etoposide induces treatment-related
acute myelocytic leukemia (t-AML) and
treatment-related myelodysplastic syn-
dromes (t-MDS), which often progress
to t-AML (Pedersen-Bjergaard et al.,
2002). Those t-AML and t-MDS are char-
acterized by balanced translocations
involving chromosome bands 11q23 or
21q22 (Ratain and Rowley, 1992). The
11q23 pathway involves activation of
the MLL gene following its translocation
and has been directly related to the trap-ping of Top2cc in the MLL gene (Lovett et al., 2001). The exact
molecular mechanisms by which the Top2cc induce the translo-
cations remain to be determined (Azarova et al., 2007; Felix et al.,
2006). Top2 subunit dissociation and exchanges have been
invoked (Pommier et al., 1988). However, the translocation
mechanisms are likely to be more complex. The carcinogenicity
of natural isoflavones has been related to the mutagenicity of
Top2cc (Deweese and Osheroff, 2009; Strick et al., 2000).
Recent studies in mice lacking Top2b suggest that etoposide-
induced carcinogenic lesions mainly involve Top2b (Azarova
et al., 2007). The development of Top2a-specific drugs is there-
fore a legitimate and novel avenue for novel inhibitors with
reduced risk of secondary malignancies.
Bacterial Type II Topoisomerases: Gyrase
and Topo IV Inhibitors Used as Antibacterials
Bacterial Type II Enzymes
DNA gyrase was identified in extracts from E. coli in 1976 by
Gellert, Mizuuchi, Nash, and coworkers during studies on the
integrative recombination of phage l (Gellert et al., 1976a). Itª2010 Elsevier Ltd All rights reserved 427
Figure 6. Inhibitors of Type IIA
Topoisomerases
(A) Inhibitors of eukaryotic Top2 enzymes. All
drugs except ICRF-187 trap Top2 cleavage
complexes and generate DNA breaks (see Fig-
ures 1F–1H). ICRF-187 is a catalytic inhibitor.
(B) Gyrase and Topo IV inhibitors from the quino-
lone family. All drugs trap cleavage complexes.
Note that the quinolone CP-115,953 traps both
eukaryotic and prokaryotic enzymes, which is
not the case in the other quinolones shown in
this panel. Also note that TAS-103 is a dual inhib-
itor of Top1 and Top2 (Wilson Byl et al., 1999).
(C) Gyrase catalytic inhibitors.
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supercoil DNA in the presence of ATP. Gyrase’s enzymatic
activity is essential for the regulation of DNA superhelicity, tran-
scription initiation and elongation, and bacterial replication.
Gyrase functions as a heterotetramer composed of two GyrA
subunits (97 kDa, 875 aa) and two GyrB subunits (90 kDa,
804 aa) (see Figures 1B, 4B, and 4C).
The second bacterial type II enzyme is Topo IV. It was discov-
ered in 1990 in a cytological screen for temperature-sensitive
mutations conferring a partition phenotype (hence the name
‘‘par’’ for the two subunits) characterized by chromosomes
that can be replicated but not partitioned, resulting in the accu-
mulation of large nucleoids in the middle of filamentous cells.
This phenotype established Topo IV as the primary decatenase
in the cell (Kato et al., 1990). Like gyrase, Topo IV functions as
a heterotetramer composed of two ParC (84 kDa, 752 aa) and
two ParE (70 kDa, 630 aa) subunits (see Figures 1B, 4B, and
4C). However, unlike gyrase, Topo IV cannot generate negative
supercoiling.428 Chemistry & Biology 17, May 28, 2010 ª2010 Elsevier Ltd All rights reservedBoth gyrase and Topo IV are capable of
removing negative or positive supercoil-
ing (Figure 5) (Wang, 2009a, 2009b).
However, Topo IV preferentially binds
and relaxes positive supercoils (Crisona
et al., 2000; Stone et al., 2003). The two
enzymes, although closely related with
respect to amino acid sequence (approx-
imately 40% sequence identity and a
much higher level of homology; see
Figure 4B), differ strikingly in their ability
to catalyze inter- versus intramolecular
strand passage reactions. Topo IV has
higher specificity for intermolecular (dec-
atenation) reactions, whereas gyrase
favors intramolecular (supercoiling) reac-
tions.
Antibacterial Topoisomerase
Inhibitors
Bacterial type II topoisomerases are
good targets for antibacterial chemo-
therapy for the following reasons: (1)
they are essential in all bacteria for repli-
cation and cell division; (2) an accumula-
tion of cleavage complexes has bacteri-
cidal (not just bacteriostatic) effect; (3)targeting bacterial type II topoisomerases is not poisonous for
human enzymes (antibacterial agents show a level of speci-
ficity/selectivity for prokaryotic enzymes at least three orders
of magnitude higher than for eukaryotic enzymes); and (4) due
to the high degree of homology between gyrase and Topo IV,
antibacterial topoisomerase inhibitors tend to target both
enzymes.
Quinolones are synthetic drugs based on the 4-oxo-1,4-dihy-
droquinolone skeleton (Figure 6B). Nalidixic acid was discovered
14 years before gyrase (Gellert et al., 1976b) as an impurity in
a batch of antimalarial chloroquine (Lesher et al., 1962). The anti-
bacterial activity of the first generation of quinolones (nalidixic
and oxolinic acids) as well as their simple synthetic route ap-
peared immediately interesting. However, their antibacterial
spectrum was limited to Gram-negative bacteria and their clin-
ical use was restricted to urinary tract infections. The introduc-
tion of a fluorine atom at position 6 (Figure 6B) and of a bulky
piperidine at position 7 broadened the antimicrobial spectrum
to Pseudomonas species and some Gram-positive organisms
Figure 7. Interfacial Inhibition
by Topoisomerase Inhibitors
(A) Intercalation of camptothecin in the DNA break
between the base pairs flanking the Top1
cleavage complex (positions 1 and +1; see
Figures 1C–1E). The basic residues that catalyze
the nucleophilic attack of DNA by the catalytic
tyrosine (Y743 in gold) are shown in blue (see
Figure 2A). The Top1 amino acid residues that
make hydrogen-bond interactions with the camp-
tothecin E ring are not shown (see Figure 4 in
Marchand et al., 2006).
(B) Overview of the Top1-DNA cleavage complex.
Top1 is in blue, DNA is in green, and camptothecin
is in purple (Ioanoviciu et al., 2005; Marchand
et al., 2006) (Protein Data Bank ID code 1T8I).
(C) Intercalation of levofloxacin in the DNA break
between the base pairs that flank the Topo IV
cleavage complex (1 and +1; see Figure 1). The
acidic residues that coordinate the Mg2+ (see
Figures 4B and 4C) are shown in red and the cata-
lytic tyrosine (Y118) in gold.
(D) Overview of the Topo IV-DNA cleavage
complex. Topo IV is in red, the DNA is in green,
and the levofloxacin molecules in both cleavage
sites are in purple (Laponogov et al., 2009) (Protein
Data Bank ID code 3K9F).
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quinolones presents substitutions at the 7 as well as at the 8
position, resulting in enhanced activity against Gram-positive
bacteria (and in most cases higher specificity for Topo IV). Moxi-
floxacin and levofloxacin (Figure 6B) are active against S. aureus
and S. pneumoniae, pathogens responsible for upper and lower
respiratory tract infections, acute otitis, and meningitis (Keating
and Scott, 2004). Moxifloxacin is also active againstMycobacte-
rium tuberculosis, which lacks Topo IV (Mdluli and Ma, 2007).
Recently, the fourth generation of fluoroquinolones has been
developed, with enhanced potency and a broader spectrum
including anaerobic coverage. Examples of this class include
gemifloxacin (Figure 6B), approved by the FDA in 2003, and
currently one of the most potent fluoroquinolones against
community-acquired pneumonia and acute bronchitis. Trova-
floxacin is also used against intra-abdominal and pelvic infec-
tions. The current new inhibitors under preclinical and clinical
investigation aremainlymolecules based on the quinolone struc-
ture; some examples are fluoroquinolones with bulkier 7 substi-
tutions (Bradbury and Pucci, 2008) and the 8-cyano-fluoroquino-
lones, naphtiridones, and nonfluorinated quinolones (Black and
Coleman, 2009). Promising nonquinolone molecules such as
the quinolines still target GyrA and ParC and show broad activity
spectrum as well as coverage against the current quinolone-
resistant strain (Black and Coleman, 2009). Other agents such
as the class of ‘‘quinolone hybrids’’ (Bradbury and Pucci, 2008)
are under investigation, but the clinical relevance of all these
new molecules has still to be proved.Chemistry & Biology 17, May 28, 2010As for eukaryotic anti-Top2 agents,
antibacterial quinolones convert bacterial
type II enzymes into potent cellular
toxins, stabilizing the cleavage com-
plexes in an open form with generation
of chromosome breaks, which culminate
in cell death (Drlica et al., 2009). Quino-lones selectively poison the GyrA subunit of gyrase and the
ParC subunit of Topo IV and interact with both GyrA and B and
ParC andE (see next section on interfacial inhibition and Figure 7)
(Drlica et al., 2009; Heddle et al., 2000; Laponogov et al., 2009).
The target preference for gyrase versus Topo IV (as well as the
appearance of mutations) seems to depend upon two factors:
the species of organism and the structure of the drug. In
Gram-negative bacteria, gyrase is the primary target of fluoro-
quinolones, whereas Topo IV is their preferential target in
Gram-positive bacteria (Drlica et al., 2009; Ferrero et al., 1994;
Pan and Fisher, 1998).
Resistance to fluoroquinolones is caused by stepwise muta-
tions in Topo IV and gyrase, leading to alterations of their binding
site. Such mutations occur primarily in an area called the quino-
lone resistance-determining region (positions 67–106 in E. coli
GyrA). Mutations in this region greatly reduce the affinity of
quinolones for the cleavage complex. Other mechanisms of
resistance include altered drug uptake, increased drug efflux,
and/or chemical drug inactivation before the quinolone reaches
its intracellular target (Drlica et al., 2009).
Gyrase and to a lesser extent Topo IV can also be targeted
in their ATP-binding sites (GyrB and ParE, respectively) (see
Figure 4). Aminocoumarins such as coumermycin A1 and novo-
biocin (Figure 6C) are antibiotics isolated from Streptomyces
strains (Heide et al., 2008). They were discovered in the 1950s,
well before the quinolones. They bind to the ATP-binding pocket
of GyrB and ParE and thereby block enzyme activity (Lewis et al.,
1996). In spite of its potent antigyrase activity, novobiocin wasª2010 Elsevier Ltd All rights reserved 429
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Reviewdiscontinued as a clinical drug because of its low bioavailability
and solubility and because of side effects. Aminocoumarins
are also toxic toward eukaryotic cells, which could be related
to their activity against the host Top2 enzymes or other ATP-
binding enzymes. Efforts are still ongoing to obtain more selec-
tive and less toxic GyrB inhibitors (Charifson et al., 2008; Oblak
et al., 2007).
Interfacial Inhibition Revealed by Topoisomerase
Inhibitors
The hypothesis that topoisomerase inhibitors trap cleavage
complexes by binding at the enzyme-DNA interface was first
proposed to account for the results of DNA-sequencing experi-
ments showing that drugs from different chemical families trap
different sites depending on the bases flanking the cleavage
sites (Capranico et al., 1990; Capranico and Binaschi, 1998;
Fortune and Osheroff, 2000; Jaxel et al., 1991; Pommier et al.,
1991). In the early 1990s, the drugs were proposed to act by
stacking between the flanking base pairs (see schemes in
Figures 1E and 1H). A second component of the drug selectivity
was related to hydrogen bonds formed between the drug and the
enzyme amino acids in the immediate vicinity of the cleaved
DNA. The stacking interfacial model accounts for the fact that
Top1 and Top2 inhibitors enhance the steady-state levels of
cleavage complexes (see Figure 1) and for the rapid reversibility
of the cleavage complexes upon drug removal.
Interfacial Complexes for Top1 Inhibitors
The interfacial stacking hypothesis was validated with the Top1
inhibitors after the resolution of cocrystals including topotecan
(Staker et al., 2002), camptothecin (Ioanoviciu et al., 2005),
indenoisoquinolines (Ioanoviciu et al., 2005), and an indolocar-
bazole derivative (Ioanoviciu et al., 2005; Marchand et al.,
2006; Pommier and Marchand, 2005) (Figures 7A and 7B). The
interfacial drug binding was also borne out from the mapping
of camptothecin-resistance point mutations (Pommier et al.,
1999), which turned out to affect those amino acid residues
that form the hydrogen bonds between the drugs and Top1
(Chrencik et al., 2004). In the case of camptothecins, three H
bonds are formed: the first between the camptothecin N-1 posi-
tion (see Figure 3A) and arginine 364, the second between the
camptothecin 20-hydroxyl and aspartate 533, and the third
between the camptothecin 17-carbonyl and asparagine 722
(see Figure 4 in Marchand et al., 2006). Mutation of that single
residue (i.e., N722S) renders Top1 immune to camptothecins,
albeit without prohibiting the formation of cocrystals (Chrencik
et al., 2004), which emphasizes the importance of each of the
H bonds for stabilizing the drug in the cleavage complex.
Interfacial Complexes for Topoisomerase II Inhibitors
The interfacial inhibitor paradigm has recently been validated
for the quinolones and Topo IV (Figures 7C–7D) (Laponogov
et al., 2009). Consistent with the studies with the anticancer
Top2 inhibitors (Capranico et al., 1990; Freudenreich and
Kreuzer, 1994; Pommier et al., 1991; Pommier and Marchand,
2005) and quinolone resistance (Yoshida et al., 1991), and in
agreement with the findings with Top1 inhibitors (see above),
moxifloxacin or levofloxacin (Figures 7C and 7D) stacks between
the base pairs flanking the cleavage site and binds at the
interface of the enzyme and DNA. As in the case of Top1 inhibi-
tors, this mechanism accounts for the inhibition of religation and430 Chemistry & Biology 17, May 28, 2010 ª2010 Elsevier Ltd All righthe accumulation of cleavage complexes produced by the
drugs.
Conclusions and Prospects
In spite of the remarkable elucidation of topoisomerase struc-
tures, enzymatic mechanisms, biological functions, and mecha-
nisms of action of inhibitors as antibacterial and anticancer
agents over the past 30 years, we only know a small number of
molecular partners (cellular proteins) of topoisomerases. There
are still no relevant inhibitors for viral and bacterial type I topoiso-
merases. The discovery of novel antibacterials not only against
type II enzymes but also against type I bacterial topoisomerases
is warranted. Such drugs could provide new therapies against
human diseases, including bacterial infections associated with
the emergence of highly resistant strains. Hopefully, the struc-
tural insight into the cleavage complexes formed by Topo IV
with DNA and quinolones will open new doors for the rational
development of more effective drugs. Novel noncamptothecin
Top1 inhibitors are beginning clinical trials and the search for
Top2 inhibitors specific for the a isoform should limit the occur-
rence of drug-induced secondary cancers. There are still no
available inhibitors for eukaryotic Top3. Such drugs would be
valuable as molecular tools and as potential novel anticancer
agents. Finally, ongoing progress in molecular genetics and
biology should enable clinicians to personalize treatments with
antitopoisomerase drugs against cancers and infectious
diseases.
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